Tryptamine Therapeutics (ASX:TYP) has provided further data from its recently completed phase 1b study utilising TRP-8803, with all key objectives met including: TRP-8803 safe at low, mid, and upper ...

Tryptamine Therapeutics has reached a milestone in development of its novel IV-infused psilocin formulation TRP-8803, with the drug meeting all phase 1b study objectives. Tryptamine Therapeutics ...

What if there was a simple blood test that could detect and screen for multiple cancers at once? This is what researcher's across the country are trying to learn in the Vanguard Study! We are looking ...

Is your favorite AI chatbot scheming against you? If "AI scheming" sounds ominous, you should know that OpenAI is actively studying this phenomenon. This week, OpenAI published a study conducted ...